The Daily Human Cost of Smoking and the Urgent Need for Better Solutions
Share
The Daily Human Cost of Smoking and the Urgent Need for Better Solutions
If you stop for a moment and think about it, chances are high that you know someone in your family, circle of friends, or community whose life has been deeply affected by cigarettes. For many people, the connection is painfully personal. A parent who struggled with lung disease. A grandparent who died of cancer. A friend who battled heart disease after decades of smoking. Cigarettes have left an unmistakable imprint on families across generations.
Few consumer products carry a legacy of harm that is so widely recognized across society. While many substances carry health risks, tobacco stands apart in one important respect: its consequences have been documented for decades and affect millions of people every year. Smoking related illnesses touch nearly every community and every healthcare system in the world. The scale of the problem is difficult to overstate.
Public health authorities have long recognized smoking as one of the most serious preventable health challenges in modern history. The U.S. Centers for Disease Control and Prevention states that “Cigarette smoking remains the leading cause of preventable disease and death in the United States.”¹ This statement alone illustrates how deeply entrenched the problem has become. Cigarettes have been widely available for generations, and despite extensive public health campaigns, the consequences continue to affect millions of families.
The same agency reports that cigarette smoking “kills more than 480,000 Americans each year.”² When that number is broken down, it becomes even more striking. More than 480,000 deaths per year means that over 1,300 Americans lose their lives every single day from smoking related causes. Every day, families lose loved ones to diseases linked to smoking.
The global numbers are even larger. According to the World Health Organization, tobacco use “kills more than 8 million people each year worldwide.”³ These deaths include both smokers themselves and individuals exposed to secondhand smoke. Across the globe, tobacco remains one of the most significant contributors to preventable illness and premature death.
Beyond mortality, smoking contributes to a wide range of chronic health conditions that affect quality of life for millions of people. Heart disease, stroke, chronic lung disease, and multiple forms of cancer have all been strongly linked to smoking. Healthcare systems across the world spend enormous resources treating illnesses that could often be prevented if smoking rates were reduced.
Despite these consequences, nicotine addiction remains widespread. Researchers estimate that more than one billion people worldwide continue to smoke cigarettes. For many smokers, quitting can be extraordinarily difficult because nicotine is a highly addictive substance and smoking often becomes intertwined with long established daily habits.
At the same time, the nicotine marketplace itself has undergone significant changes.
Over the past decade, electronic cigarettes and vaping devices have emerged as an alternative nicotine delivery system. Many companies have marketed vaping products as alternatives to combustible tobacco, and millions of consumers have adopted them. However, regulators and health authorities continue to study their long term health impact and their role in nicotine addiction.
The Centers for Disease Control explains that “Most e-cigarettes contain nicotine,” and further notes that “Nicotine is highly addictive.”⁴ These facts have led many public health experts to express concern that new nicotine delivery technologies may sustain addiction rather than eliminate it.
Another major area of concern has been youth exposure to nicotine products. According to the CDC, “E-cigarettes are the most commonly used tobacco product among U.S. youth.”⁵ As vaping devices became widely available, their adoption among teenagers and young adults quickly drew the attention of regulators and educators.
Global youth usage has also become a growing public health issue. A report citing World Health Organization data estimates that “At least 15 million children aged 13 to 15 are estimated to use e-cigarettes globally.”⁶ The rapid growth of youth vaping has raised questions about how early exposure to nicotine may influence long term health outcomes and addiction patterns.
Researchers have also studied the composition of vapor produced by electronic cigarettes. According to the CDC, “E-cigarette aerosol can contain harmful substances, including nicotine, cancer-causing chemicals, heavy metals such as nickel, tin, and lead, volatile organic compounds, and ultrafine particles that can be inhaled deep into the lungs.”⁷ These findings continue to drive research into the potential health implications of long term vaping.
Another important area of research examines how vaping may influence future smoking behavior. A large review of studies found that young people who vape are “three times as likely to start smoking.”⁸ This relationship between vaping and traditional cigarette use has become a major area of discussion among policymakers and public health researchers.
Taken together, these developments illustrate the complexity of the modern nicotine marketplace. While traditional cigarette use has declined in some regions, nicotine addiction remains widespread. At the same time, the emergence of new nicotine delivery systems has introduced additional challenges for regulators and healthcare systems seeking to reduce nicotine dependence.
For policymakers and healthcare providers, the objective remains clear: help individuals break nicotine addiction entirely.
The size of the smoking cessation market highlights why innovation in this area has drawn increasing attention from healthcare leaders and investors. With more than one billion smokers worldwide and growing regulatory pressure on both cigarettes and vaping products, governments and healthcare systems are actively searching for more effective solutions that help people quit.
Even small improvements in cessation success rates could translate into enormous public health benefits. Millions of lives could potentially be improved if more smokers were able to transition away from nicotine dependence.
For this reason, technologies designed to help smokers move beyond nicotine addiction entirely are attracting increasing attention within the healthcare and investment communities.
Redwood Scientific Technologies is focused on developing nicotine free technologies designed to support smoking and vaping cessation. Through its TBX FREE and TBX VAPE FREE platforms, the company is developing oral thin film technologies intended to address behavioral patterns associated with smoking without introducing nicotine.
Unlike many nicotine replacement products that continue delivering nicotine to the user, Redwood’s approach focuses on nicotine free alternatives intended to support individuals seeking to transition away from both cigarettes and nicotine based products.
As awareness of nicotine addiction continues to grow and regulatory pressure increases, solutions designed to help individuals eliminate nicotine dependence entirely may play an increasingly important role in the future of global health.
The global shift away from smoking is already underway.
For investors, policymakers, and healthcare leaders, the question is no longer whether this transition will occur. The question is which technologies and companies will lead the development of the next generation of smoking cessation solutions.
Sources and References
- U.S. Centers for Disease Control and Prevention
https://www.cdc.gov/tobacco/campaign/tips/resources/data/cigarette-smoking-in-united-states.html - U.S. Centers for Disease Control and Prevention
https://www.cdc.gov/tobacco/campaign/tips/resources/data/cigarette-smoking-in-united-states.html - World Health Organization
https://www.who.int/news-room/fact-sheets/detail/tobacco - U.S. Centers for Disease Control and Prevention
https://www.cdc.gov/tobacco/e-cigarettes/health-effects.html - U.S. Centers for Disease Control and Prevention
https://www.cdc.gov/tobacco/e-cigarettes/youth.html - Reuters citing World Health Organization data
https://www.reuters.com/business/healthcare-pharmaceuticals/who-estimates-least-15-million-teenagers-use-e-cigarettes-worldwide-2025-10-06/ - U.S. Centers for Disease Control and Prevention
https://www.cdc.gov/tobacco/basic_information/e-cigarettes/about-e-cigarettes.html - Research review reported in The Guardian
https://www.theguardian.com/society/2025/aug/19/young-vape-users-three-times-as-likely-to-start-smoking-study
About Redwood Scientific Technologies, Inc.
Redwood Scientific Technologies, Inc. is focused on developing innovative nicotine free technologies designed to help smokers transition away from combustible cigarettes and nicotine based products. The company’s TBX FREE and TBX VAPE FREE platforms are designed to address the behavioral and sensory aspects of smoking cessation while eliminating nicotine.
Redwood has previously achieved large scale commercial distribution of its oral thin film technologies and continues to advance new solutions designed for the global smoking cessation market. With more than 1 billion smokers worldwide and increasing regulatory pressure on both cigarettes and vaping products, demand for effective nicotine free alternatives continues to grow.
Additional information about Redwood Scientific Technologies can be found at
Additional Company Disclosure
Redwood Scientific Technologies, Inc. is currently advancing the development of its nicotine free cessation technologies, including TBX FREE and TBX VAPE FREE. The company is in the process of completing required clinical validation through controlled research protocols.
Redwood’s products are not currently being marketed or sold. The company intends to complete a double blind placebo controlled efficacy study covering both product platforms prior to any commercial launch. These studies are designed to evaluate the effectiveness of the products in supporting smoking and vaping cessation and to provide data suitable for scientific publication.
Until those studies are completed and the company finalizes its clinical and regulatory strategy, Redwood Scientific Technologies does not offer these products for sale.
In addition, Redwood’s commercial strategy is structured as a business to business distribution model. The company does not sell products directly to end users or directly to consumers. Instead, Redwood intends to work through licensed distributors, healthcare partners, and institutional channels for future product distribution.
Forward Looking Statement Notice
Certain statements contained in this article constitute forward looking statements within the meaning of applicable securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Forward looking statements include, but are not limited to, statements regarding clinical studies, product development, regulatory strategy, commercialization plans, and market opportunities.
Readers and investors should not place undue reliance on forward looking statements, which speak only as of the date of publication.
This article is provided for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities.